..............the first approved neurodevelopment drugs that _also_ has potential for wider application in a CNS market with few successful drugs makes Neuren just that much more valuable.
Out of interest, does the FDA approval (and FDA) afford Doctors to prescribe Trofinetide to patients of other neurological disorders as a possible alternate option for treatment, or is it purely restricted to Retts' sufferers?
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-22
-
- There are more pages in this discussion • 142 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |